Uses of Solian

Solian is an antipsychotic drug with the main active ingredient being Amisulpride. Solian is indicated in the treatment of acute and chronic schizophrenia with positive or negative symptoms. The following article provides you with information on indications and precautions when using Solian.

Solian drug has the main active ingredient is Amisulpride, the drug is prepared in the form of tablets with the strength of 200mg and 400mg.
Amisulpride binds selectively with high affinity to dopamine receptors D2 and D3, whereas it has no affinity for D1, D4, and D5. Amisulpride also has no affinity for serotonin, alpha adrenergic, cholinergic, histamine H1 receptors. In addition, Amisulpride also does not bind to the sigma site. Amisulpride blocks presynaptic D2/D3 receptors, causing dopamine release.
Amisulpride pharmacodynamics explains why Solian is effective for both negative and positive symptoms of schizophrenia.

2.1. Indications Solian is indicated for the treatment of acute and chronic schizophrenia with positive symptoms (such as thought disturbances, hallucinations, delusions) and/or negative symptoms. (including withdrawal from social life), including patients with predominant negative symptoms.
2.2. Contraindications Solian is contraindicated for use in the following cases:
Hypersensitivity to Amisulpride or any component of Solian. Prolactin-dependent tumors such as pituitary adenomas or breast cancer. Pheochromocytoma. Children under 15 years old (before puberty). Pregnant. Breastfeeding women. Do not combine Solian with Levodopa.

3.1. How to take Solian is taken orally. Swallow the tablet whole with water, do not chew or crush the tablet. Take Solian before meals. If you feel that the effect of Solian is too strong or too weak, do not change the dose on your own and consult your doctor.
3.2. Dosage For acute phase: Recommended dose 400mg - 800mg/day. Dosage may be adjusted according to individual patient response. In some cases the daily dose can be increased to 1200mg/day. The dose of 1200 mg/day has not been extensively evaluated for safety and is therefore not recommended. For patients with both positive and negative symptoms, the dose should be adjusted for optimal control of positive symptoms. Maintain the lowest clinically effective dose of Solian. For patients with predominantly negative symptoms, the dose ranges from 50 mg to 300 mg/day. The dose of Solian should be adjusted according to the individual patient's response. Solian can be used once a day when the dose is 300mg or less, in case of higher doses, it should be divided into 2 times / day. Elderly: The safety of Amisulpride has been studied in the elderly. Use Solian with caution in the elderly due to the risk of hypotension and sedation. In some cases, a dose reduction may be necessary because the patient may have impaired renal function. Children: Data on the safety and efficacy of amisulpride in children from puberty to 18 years of age have not been established, so the use of Solian is not recommended in this population. The use of Solian is contraindicated in children before puberty because the safety of Solian has not been established in this age group. Patients with renal impairment: Solian is eliminated by the kidneys. Creatinine clearance about 30 - 60mL/min: Take 1/2 dose. Creatinine clearance about 10 - 30mL/min: Take 1/3 of the dose. Patients with hepatic impairment: Solian is poorly metabolized by the liver, so it is not necessary to reduce the dose. 3.3. Solian drug overdose and management Symptoms of drug overdose are mainly side effects of the drug with more seriousness. Symptoms of Solian overdose: hypotension, sedation, somnolence, extrapyramidal symptoms and coma. Fatal cases of Solian overdose have been reported mainly with concomitant use of other antipsychotics. In case of acute Solian overdose, the possibility of multiple drug use should be considered.
Management: Hemodialysis is not effective for Solian overdose and there is no specific antidote. Therefore, symptomatic and supportive measures are essential, such as monitoring of vital functions. Because of the risk of QT prolongation, monitor the ECG until the patient recovers. If the patient develops severe extrapyramidal symptoms, use anticholinergics.

Neuroleptic malignant syndrome (high fever, altered consciousness, autonomic dysfunction, muscle stiffness, increased CPK) may occur with the use of Solian. In case of high fever, especially when taking Solian in high doses, it is necessary to stop all antipsychotic drugs including Solian. Hyperglycemia: Has been reported in patients treated with Amisulpride. Therefore, patients with a confirmed diagnosis of diabetes or at risk of diabetes, before starting treatment with Amisulpride should closely monitor blood sugar. Patients with Renal Impairment: Amisulpride is eliminated by the kidneys, requiring dose adjustment or intermittent therapy in patients with renal impairment. Epilepsy patients: Solian lowers the seizure threshold, and caution and close monitoring should be exercised when using Solian in patients with a history of seizures. Elderly Patients: Use Solian with caution in elderly patients due to the risk of hypotension or sedation. It may be necessary to reduce the dose of Solian due to impaired renal function of the patient. Parkinson's: Solian can make the condition worse, so only use Solian in Parkinson's patients when absolutely necessary. Acute withdrawal symptoms such as nausea, vomiting and insomnia have been reported following abrupt discontinuation of high doses of sedatives. Recurrence of psychotic symptoms and occurrence of involuntary movement disorders (neurodystrophy, dyskinesia, and dystonia) have also been reported. Therefore, when discontinuing Solian, it is necessary to gradually reduce the dose and avoid sudden discontinuation of Solian. QT interval prolongation: Amisulpride should be used with caution in patients with cardiovascular disease or a family history of prolonged QT interval; Concomitant use of Solian with neuroleptics should be avoided. Older adults with dementia: Several clinical studies have shown that older adults with dementia who are treated with antipsychotics have a higher risk of death. Solian must not be used to treat dementia-related conduct disorder. Venous Thrombosis: Cases of venous thrombosis have been reported in patients receiving antipsychotics. In addition, patients treated with antipsychotics often have risk factors for VTE, so all risk factors for VTE should be identified before, during, and after treatment. Use Solian. Breast cancer: Solian increases prolactin levels, so caution should be exercised when Solian is used in patients with a history or family history of breast cancer. Amisulpride may increase prolactin levels. Cases of benign pituitary adenomas have been observed during treatment with Amisulpride. In cases where prolactin levels are very high or the patient has clinical signs of pituitary tumor, a pituitary angiogram should be performed. If a diagnosis of pituitary tumor is confirmed, treatment with Solian must be discontinued. Hemocytopenia including leukopenia, granulocytopenia, and neutropenia has been reported with Amisulpride. Unexplained infection or fever may be evidence of blood dysfunction and require immediate blood tests. Solian contains lactose and should not be used in patients with impaired glucose tolerance, Lapp-lactase deficiency or impaired glucose-galactose metabolism. Ability to drive and use machines: May cause drowsiness, blurred vision, affect the ability to drive and use machines. Pregnancy: Amisulpride crosses the placenta. Clinical data on the safety of amisulpride in pregnant women are limited. The use of Solian during pregnancy is not recommended unless the potential benefit to the mother outweighs the risk. Neonates exposed to antipsychotics (including Solian) during the third trimester of pregnancy are at increased risk of developing withdrawal symptoms of varying severity and duration, and/or extrapyramidal symptoms. . There have been reports of symptoms appearing in children such as respiratory depression, somnolence, lethargy or eating disorders, agitation, spasticity, tremor, hypotonia. In this case, the infant should be carefully monitored. Lactation: Amisulpride is excreted in human milk, but blood levels in the nursing infant have not been evaluated. There is not enough information available on the effects of Amisulpride when used in infants/children. Weigh the benefits of breastfeeding against the benefits of treatment for the mother to decide whether to discontinue nursing or discontinue Solian.

When using Solian in treatment, you may experience some of the following undesirable effects:
Nerve: Very common: Extrapyramidal symptoms may occur such as tremor, spasticity, movement disorders , increased salivation. The incidence of extrapyramidal symptoms depends on the dose of Solian, and the rate is very low when treating patients with mainly negative symptoms at a dose of 50-300mg/day. Common: Drowsiness, acute neuromotor disturbances (eye rotation, convulsive torticollis, jaw stiffness) may occur, lethargy. Uncommon: tardive dyskinesia characterized by rhythmic, involuntary movements mainly of the face or tongue - common, often with long-term drug use, convulsions. Rare: Neuroleptic malignant syndrome is a potentially fatal complication. Restless leg syndrome. Psychiatric: Insomnia, confusion, anxiety, restlessness, orgasmic disorder. Gastrointestinal: Constipation, vomiting, nausea, dry mouth, increased liver enzymes. Skin: Rash, urticaria. Cardiovascular: Hypotension, bradycardia, hypertension may occur. Venous thromboembolism, including deep vein thrombosis, pulmonary embolism. Endocrine: Amisulpride causes an increase in prolactin levels and is reversible upon discontinuation of Solian. This can lead to amenorrhea, increased lactation, breast tenderness, gynecomastia, and erectile dysfunction. Immunity: Allergic reactions. Eyes: Blurry vision. Hematology: Leukopenia, granulocytopenia, neutropenia. Metabolism: hypertriglyceridemia, hypercholesterolemia, hyperglycemia.

Levodopa: Contraindicated in combination with the drug Solian. Alcohol: Should not be used concurrently with Solian because the drug increases the effect of alcohol on the central nervous system. CNS depressants such as narcotics, anesthetics, analgesics, sedatives, H1 antihistamines, benzodiazepines and other anxiolytics; antihypertensive drugs: should be considered when combining Solian with these drugs. Clozapine: Increases plasma concentration of Amisulpride. Drugs capable of prolonging the QT interval such as class IA antiarrhythmic drugs (Quinidine, Disopyramide), class III antiarrhythmic drugs (Amiodarone, Sotalol).